![PhysioStim appoints Dr. Bruno Le Grand as scientific advisor](https://ala.associates/wp-content/uploads/2020/11/Photo-BLG-1080x675.jpeg)
![PhysioStim appoints Dr. Bruno Le Grand as scientific advisor](https://ala.associates/wp-content/uploads/2020/11/Photo-BLG-1080x675.jpeg)
![Minoryx’s preclinical data for leriglitazone in Friedreich’s Ataxia published in Neurobiology of Disease Journal](https://ala.associates/wp-content/uploads/2020/11/minoryx27099-LR-cut-679x675.jpg)
Minoryx’s preclinical data for leriglitazone in Friedreich’s Ataxia published in Neurobiology of Disease Journal
![European Investment Bank provides Minoryx with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseases](https://ala.associates/wp-content/uploads/2020/10/EIB-et-EC-1080x675.png)
European Investment Bank provides Minoryx with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseases
![Tollys extends its executive management team with appointment of Bettina Werle as CSO](https://ala.associates/wp-content/uploads/2020/10/Bettina-Werle-1024x675.jpg)
Tollys extends its executive management team with appointment of Bettina Werle as CSO
![Amolyt Pharma annonce la première administration de l’AZP-3601 dans son essai clinique de phase 1](https://ala.associates/wp-content/uploads/2020/12/1-1-960x675.jpg)
Amolyt Pharma annonce la première administration de l’AZP-3601 dans son essai clinique de phase 1
![Advent France Biotechnology appoints Geoffroy de Ribains as operating partner](https://ala.associates/wp-content/uploads/2020/12/Geoffroy-de-Ribains-853x675.jpg)
Advent France Biotechnology appoints Geoffroy de Ribains as operating partner
![Kymos and Prolytic merge to become Kymos Group, a top pan-European CRO dedicated to innovative pharmaceuticals](https://ala.associates/wp-content/uploads/2020/09/Prolytic-and-Kymos-management-1080x675.jpg)
Kymos and Prolytic merge to become Kymos Group, a top pan-European CRO dedicated to innovative pharmaceuticals
![Minoryx Therapeutics and Sperogenix Therapeutics enter into exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau](https://ala.associates/wp-content/uploads/2020/09/Sans-titre-2.png)
Minoryx Therapeutics and Sperogenix Therapeutics enter into exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau
![PDC*line Pharma doses first patient with high dose in ongoing PDC-LUNG-101 clinical trial](https://ala.associates/wp-content/uploads/2020/09/PDCline-tetiere-HOME-HDEF-2-1080x675.jpg)
PDC*line Pharma doses first patient with high dose in ongoing PDC-LUNG-101 clinical trial
![Advanced BioDesign welcomes Prof. Pierre Tambourin to its scientific advisory board](https://ala.associates/wp-content/uploads/2020/09/Photo-Pierre-Tambourin-1080x675.jpg)